IDT Biologika has dedicated its first U.S. vaccine manufacturing facility in Rockville, MD. The new facility provides a bridge between preclinical development and Phase II clinical trials with capabilities including, process development, cell banking, cGMP manufacturing, purification and formulation, and fill and finish.   The facility is BSL-2 compliant and meets both U.S. FDA and European Medicines Agency (EMA) standards. IDT shares the 75,000-sq.-ft. building with Aeras, a nonprofit, global...